Skip to content

Micropulse Laser Trabeculoplasty (532nm) Versus Conventional Laser Trabeculoplasty (532nm)

Micropulse Laser Trabeculoplasty (532nm) Versus Conventional Laser Trabeculoplasty (532nm) in Open Angle Glaucoma Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01788319
Enrollment
30
Registered
2013-02-11
Start date
2013-02-28
Completion date
2015-06-30
Last updated
2015-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Open Angle Glaucoma

Keywords

laser trabeculoplasty, glaucoma

Brief summary

This study will investigate if micropulse laser trabeculoplasty (532nm) is as effecttive as or better than the conventional laser trabeculoplasty (532nm), it might be a new treatment strategy for glaucoma patients. It is done with a laser device that can also be used for many other ophthalmic applications, thus reducing the economic burden of treatment.

Interventions

PROCEDURElasertrabeculoplasty

Sponsors

Universitaire Ziekenhuizen KU Leuven
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* individuals over 18 years old * willing to sign an informed consent and able to comply the requirements of the study * having no other ocular diseases besides glaucoma

Exclusion criteria

* history of ocular trauma * intraocular surgery (except for phaco) * pigment dispersion and exfoliation glaucoma

Design outcomes

Primary

MeasureTime frame
to compare the intraocular pressure reduction with the micropulse laser trabeculoplasty (532nm) versus the conventional laser trabeculoplasty (532nm)one year of follow-up

Secondary

MeasureTime frame
Secondary the complication rate between the two techniques will be comparedone year of follow up

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026